Celcuity's Gedatolisib Phase 3 Trial Achieves Primary Endpoint in PIK3CA Mutant Breast Cancer

summarizeSummary

Celcuity reported positive Phase 3 trial results for gedatolisib in PIK3CA mutant breast cancer, showing significant improvement in progression-free survival and paving the way for an sNDA submission.

check_boxKey Events

• Positive Phase 3 Trial Results

  The PIK3CA mutant cohort of the VIKTORIA-1 trial for gedatolisib achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of care.

• Expanded Market Potential

  This success in the PIK3CA mutant population significantly broadens the addressable market for gedatolisib, complementing the existing FDA Priority Review for the PIK3CA wild-type cohort.

• Planned sNDA Submission

  Celcuity intends to submit these positive data to the FDA as a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting.

• Favorable Safety Profile

  Both gedatolisib regimens were generally well tolerated with manageable safety profiles and no new safety signals.

auto_awesomeAnalysis

Celcuity Inc. announced highly positive topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib. The drug demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in both triplet and doublet regimens, with a manageable safety profile. This success significantly expands the potential market for gedatolisib, building on the existing FDA Priority Review for the PIK3CA wild-type cohort. The company plans to submit these data for a supplemental New Drug Application (sNDA) and present them at the 2026 ASCO Annual Meeting, marking a critical step towards broader commercialization and addressing a significant unmet medical need in advanced breast cancer.